fashion -WSS

fashion

author：hotspot 2025-10-02 15:43:17 - browse：9

The Senate has set its eyes on regulating insurance plans for some of the most vulnerable patients in the U.S. — the 12.5 million people eligible for both Medicare and Medicaid.

“They’re a complex group of people with a lot of chronic conditions — mental illness, frailty, disability,” said Jose Figueroa, an internal medicine physician and health policy expert at Brigham and Women’s Hospital. Over a third of these dual-eligible beneficiaries have less than a high school education, and about 90% make less than $20,000 per year.

Just around 15% of beneficiaries are eligible for both Medicare and Medicaid, but they account for a third of these programs’ spending — around $440 billion — and still don’t receive better health care, Sen. Bill Cassidy (R-La.) pointed out in a JAMA viewpoint published earlier this month. “The root cause of worse outcomes despite spending more money is a lack of coordination of care,” Cassidy wrote.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Goldman Sachs launches $650M fund for life science investments

WSS

FDA panel endorses Alnylam’s heart drug — after picking it apart

PEPFAR is under serious threat — and so is global health

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

AdventHealth escalates lawsuit against insurance vendor Multiplan

GSK Flovent asthma inhalers replaced by authorized generics

3 medical device trends to watch in 2024

explore

fashion

leisure time

How one medical school became remarkably diverse

Chronically ill young patients struggle to find fertility info

Wildfire smoke exposes gaps in outdoor worker protections

Burning questions for the 2024 JPM Healthcare Conference

ChatGPT in medicine: STAT answers readers' burning questions

White House finalizes ITC's import ban of latest Apple Watches

How to save PrEP access — and even expand it

New weight loss drugs vying to be the next Wegovy or Mounjaro

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

WATCH: Why do bright lights make us see spots?

leisure time

WATCH: Why do bright lights make us see spots?

New weight loss drugs vying to be the next Wegovy or Mounjaro

3 medical device trends to watch in 2024

GSK Flovent asthma inhalers replaced by authorized generics

Acelyrin, a rare IPO success, stumbles in its first big test

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

knowledge

hotspot

knowledge

hotspot